Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study

NACompletedINTERVENTIONAL
Enrollment

358

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

October 4, 2021

Study Completion Date

October 4, 2021

Conditions
Digital Acuity Product
Interventions
DEVICE

Visibly Digital Acuity Product

"The order of testing (two VDAP home environments and ETDRS) will be randomly assigned for each subject as one of four sequences:~1. V1, E, V2~2. E, V1, V2~3. V2, E, V1~4. E, V2, V1~Where E denotes the ETDRS assessment, V1 denotes the VDAP assessment in home environment 1, and V2 denotes the VDAP assessment in home environment 2.~The randomization will be blocked in groups of 4 subjects to ensure balance for the VA testing sequences."

Trial Locations (3)

28150

Core, Inc, Shelby

38119

Total Eye Care, Memphis

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

Visibly

INDUSTRY

NCT05026658 - Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study | Biotech Hunter | Biotech Hunter